Published in Cancer Weekly, January 14th, 2003
Erin Gatza, at the University of Michigan Medical School, and Craig Y. Okada, at the University of Michigan and Veterans Administration Ann Arbor Health Care Systems, compared the efficacy of C6VL-DC vaccines with that of vaccines containing a conjugate of the T-cell receptor (TCR) Id protein and keyhole limpet hemocyanin (KLH) with the adjuvant QS-21.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.